ArticleJournal of fungi (Basel, Switzerland)2026
Clinical Significance of Serum (1→3)-β-D-Glucan Positivity in Cryptococcosis: A Retrospective Cohort Study.
Article in Journal of fungi (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptococcosis is associated with negative serum (1→3)-β-D-glucan (BDG) results, but the clinical significance of serum BDG (sBDG) positivity is unclear. We characterized the clinical features of sBDG-positive cryptococcosis in patients with cryptococcal disease. We measured the sBDG levels and classified patients as BDG-positive (>11 pg/mL) or BDG-negative. Clinical characteristics, diagnostic modalities, antifungal treatment, post-treatment BDG level changes, and 90-day cryptococcosis-related mortality were compared. BDG-positive patients showed disseminated cryptococcosis, higher inflammatory marker levels, lower serum albumin levels, higher culture positivity rates, and higher cryptococcal antigen titers than BDG-negative patients. Combination antifungal therapy was administered more frequently in the BDG-positive group; repeat measurements in 15 patients showed a significant decrease in sBDG levels. The 90-day mortality rate was significantly higher in the BDG-positive than in the BDG-negative group (37.5% vs. 3.9%), and overall survival was significantly lower. sBDG levels may be elevated in cases of disseminated or severe disease. Serum BDG positivity may reflect a higher fungal burden, greater disease severity, and poorer short-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.